EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKIs) are an essential clan of medications used to decrease the activity of EGFR, making targeting it a cornerstone of NSCLC treatment (Ma et al., 2014; Gelatti, Drilon & Santini, 2019).